Holen Sie sich die Stockscreener-App
104.09
1.57%
-1.665
Handel nachbörslich:
104.10
0.005
+0.00%
Schlusskurs vom Vortag:
$105.76
Offen:
$105.5
24-Stunden-Volumen:
204.56K
Relative Volume:
0.35
Marktkapitalisierung:
$8.08B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-224.29M
KGV:
-26.69
EPS:
-3.9
Netto-Cashflow:
$-185.06M
1W Leistung:
+0.28%
1M Leistung:
-4.55%
6M Leistung:
+31.55%
1J Leistung:
+26.85%
1-Tages-Spanne:
$103.30
$106.08
1-Wochen-Bereich:
$102.09
$107.14
52-Wochen-Spanne:
$55.53
$112.88
Nuvalent Inc Stock (NUVL) Company Profile
Firmenname
Nuvalent Inc
Sektor
Branche
Telefon
508-446-2272
Adresse
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Vergleichen Sie NUVL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
104.09 | 8.21B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.90 | 117.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.97 | 82.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.59 | 52.94B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
844.92 | 52.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.88 | 37.84B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-11-12 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-10-16 | Fortgesetzt | Stifel | Buy |
| 2025-10-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-09-04 | Fortgesetzt | Guggenheim | Buy |
| 2025-09-03 | Eingeleitet | Raymond James | Outperform |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-03-14 | Hochstufung | UBS | Neutral → Buy |
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-24 | Eingeleitet | UBS | Neutral |
| 2024-08-29 | Eingeleitet | Barclays | Overweight |
| 2024-04-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-01 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | Fortgesetzt | Guggenheim | Buy |
| 2024-02-23 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-27 | Eingeleitet | Stifel | Buy |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-24 | Eingeleitet | Guggenheim | Buy |
| 2023-01-18 | Eingeleitet | Wedbush | Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
Alle ansehen
Nuvalent Inc Aktie (NUVL) Neueste Nachrichten
Nuvalent (NUVL): Assessing an Expensive-Looking Valuation After a Strong Multi-Year Share Price Run - Yahoo Finance
Nuvalent, Inc. $NUVL Shares Bought by Voya Investment Management LLC - MarketBeat
Nuvalent files for mixed shelf offering size not disclosedSEC filing - marketscreener.com
Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Malaysian Reserve
Cancer-focused biotech Nuvalent to speak at major JPM healthcare event - Stock Titan
Technical Reactions to NUVL Trends in Macro Strategies - Stock Traders Daily
What drives Nuvalent Inc stock priceStock Buyback Updates & Follow Top Performers in the Community - earlytimes.in
Why Nuvalent Inc. stock remains a top recommendationJuly 2025 WrapUp & High Accuracy Swing Trade Signals - Улправда
Can Nuvalent Inc. stock reach $100 price target2025 Big Picture & Proven Capital Preservation Methods - Улправда
JPMorgan Chase & Co. Lowers Nuvalent (NASDAQ:NUVL) Price Target to $145.00 - MarketBeat
Aug Sentiment: Is Nuvalent Inc. stock a defensive play in 2025Weekly Loss Report & Community Trade Idea Sharing Platform - DonanımHaber
Is Nuvalent Inc. stock a defensive play in 20252025 Key Lessons & Daily Stock Momentum Reports - DonanımHaber
Certain Options of Nuvalent, Inc. are subject to a Lock-Up Agreement Ending on 19-DEC-2025. - marketscreener.com
66,836,884 Common Stock of Nuvalent, Inc. are subject to a Lock-Up Agreement Ending on 19-DEC-2025. - marketscreener.com
Analysts Are Bullish on Top Healthcare Stocks: Nuvalent (NUVL), Novan (NOVN) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Novan (NOVN) - The Globe and Mail
UBS reiterates Buy rating on Nuvalent stock, citing Royalty Pharma deal - Investing.com Canada
[8-K] Nuvalent, Inc. Reports Material Event | NUVL SEC FilingForm 8-K - Stock Titan
Nuvalent’s Royalty Interest Acquired by Royalty Pharma - TipRanks
Nuvalent Acknowledges Royalty Pharma's Acquisition of Royalty Interest - TradingView — Track All Markets
Royalty Pharma Acquires Royalty Interest in Nuvalent's Potential Lung Cancer Therapies - marketscreener.com
Royalty Pharma acquires royalty interest in Nuvalent's neladalkib and zidesamtinib for up to $315 million - marketscreener.com
Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million - Quiver Quantitative
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million - marketscreener.com
Royalty Pharma (Nasdaq: RPRX) buys Nuvalent NSCLC royalties for up to $315M - Stock Titan
Nuvalent announces public offering of common stock - MSN
Nuvalent, Inc. $NUVL Shares Acquired by Braidwell LP - MarketBeat
Is Nuvalent Inc stock a defensive play in 2025Trade Analysis Summary & Expert Curated Trade Setup Alerts - moha.gov.vn
Natixis Makes New $1.75 Million Investment in Nuvalent, Inc. $NUVL - MarketBeat
Insider Selling: Nuvalent (NASDAQ:NUVL) CFO Sells 7,084 Shares of Stock - MarketBeat
Nuvalent (NUVL) director discloses RSU and stock option acquisitions - Stock Titan
Nuvalent, Inc. (NUVL) is a buy on lung cancer treatment prospects - MSN
HighVista Strategies LLC Has $3.85 Million Stake in Nuvalent, Inc. $NUVL - MarketBeat
Nuvalent appoints Ron Squarer to board of directors By Investing.com - Investing.com Nigeria
Trading the Move, Not the Narrative: (NUVL) Edition - news.stocktradersdaily.com
Insider Sell Alert: Alexandra Balcom Sells Shares of Nuvalent In - GuruFocus
Nuvalent Appoints Ron Squarer to Board of Directors - GuruFocus
Nuvalent appoints Ron Squarer to board of directors - Investing.com
Nuvalent Insider Sold Shares Worth $781,537, According to a Recent SEC Filing - marketscreener.com
Nuvalent CFO Alexandra Balcom Sells Over 7,000 Shares - TradingView — Track All Markets
Ron Squarer Joins Nuvalent Board as Independent Director - TipRanks
Nuvalent, Inc. Announces Board Changes - TradingView — Track All Markets
Nuvalent (Nasdaq: NUVL) taps Ron Squarer for board as zidesamtinib launch prep builds - Stock Titan
Nuvalent (NUVL) Valuation After FDA Breakthrough Designation and Investor Optimism in Lung Cancer Franchise - Sahm
Nuvalent, Inc. $NUVL Shares Acquired by Walleye Capital LLC - MarketBeat
Stempoint Capital LP Has $4.57 Million Stake in Nuvalent, Inc. $NUVL - MarketBeat
Nuvalent’s Clinical and Financial Momentum Captivates Investors - AD HOC NEWS
Nuvalent (NUVL) price target increased by 11.46% to 142.80 - MSN
Ron Squarer joins Nuvalent board as independent director - MSN
Nuvalent, Inc. (NUVL) is a Buy On lung Cancer Treatment Prospects - Insider Monkey
CFO Balcom Files To Sell 7,084 Of Nuvalent Inc [NUVL] - TradingView — Track All Markets
Finanzdaten der Nuvalent Inc-Aktie (NUVL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.08%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):